GB2616294A — Composition for use
Assigned to Hyphens Pharma Pte Ltd · Expires 2023-09-06 · 3y expired
What this patent protects
A composition for use in a method of treating moderate atopic dermatitis (also known as atopic eczema) is provided, wherein the composition is topically applied on the skin at least two times a day, wherein the composition has a pH in the range of 2.7 to 5.0 and comprises: a poly…
USPTO Abstract
A composition for use in a method of treating moderate atopic dermatitis (also known as atopic eczema) is provided, wherein the composition is topically applied on the skin at least two times a day, wherein the composition has a pH in the range of 2.7 to 5.0 and comprises: a polyhydroxy acid and a zinc salt of its conjugate base, wherein polyhydroxy acid is selected from lactobionic acid, gluconolactone/gluconic acid, or a combination of lactobionic acid and gluconolactone/gluconic acid; a partition coefficient enhancer selected from propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, 1,5 pentane diol, or a combination thereof; and a diffusion coefficient enhancer which is selected from a C12 to C14 straight chain fatty acid or a C14 straight chain primary alcohol. Preferably the partition coefficient enhancer is present in an amount of 15-30% w/w of the composition, and the diffusion coefficient enhancer is preferably present in an amount of 1.0-2.0% w/w of the composition. Preferably the composition is free of steroids and topical calcineurin inhibitors.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.